Reporting owner · CIK 0001881190

Gheuens Sarah

SEC Form 4 history for the last 180 days across 1 company, 6 transactions and 1 filing.

CMOChief Medical OfficerAGIOS PHARMACEUTICALS, INC.
Open-market transaction mix0% buys0 buys · 2 sales

Period: Last 180 days

Trade dates in this period: Oct 21, 2026 – Oct 22, 2026

Transaction history, summary figures and purchase returns cover the last 180 days. Earlier activity is excluded from those sections.

Filings1Form 4 records
Buying$00 purchases
Selling$74.6k2 sales
Net value−$74.6kBuys minus sells · disclosed values

Latest insider transactions

Form 4 filings from the last 180 days.
Gheuens Sarah transactions · 20 per page
CompanyActivityDisclosed valueFiled (ET)
AGIOAGIOS PHARMACEUTICALS, INC.
CMO
CMO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
Derivative securitySEC filing ↗
$0View disclosure →
AGIOAGIOS PHARMACEUTICALS, INC.
CMO
CMO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
Derivative securitySEC filing ↗
$0View disclosure →
AGIOAGIOS PHARMACEUTICALS, INC.
CMO
CMO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$18.8kView disclosure →
AGIOAGIOS PHARMACEUTICALS, INC.
CMO
CMO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
$12.5kView disclosure →
AGIOAGIOS PHARMACEUTICALS, INC.
CMO
CMO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$55.9kView disclosure →
AGIOAGIOS PHARMACEUTICALS, INC.
CMO
CMO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
$37.2kView disclosure →

Latest Form 4 facts

Quick context from source filings

Latest open-market transaction

The insider reported a sale at AGIOS PHARMACEUTICALS, INC. on Oct 22, 2026 valued at $18,760.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Monthly open-market activity

Last 1 reported month · purchases and sales

View exact monthly values
Monthly open-market source values
MonthPurchasesSalesBuy valueSale valueNet value
Oct 202602$0$74,642.17−$74,642.17

Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.

Ownership and transaction size

Ownership and ticket size

Average P/S size$37.3k
Median P/S size$37.3k
Direct6
Indirect0
Oct 22, 2026exercise

Filing-only signals

Deterministic matches in this insider's history

Associated companies

Counts cover all available history, including outside the summary period

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
No open-market purchases in the last 180 days

A 90-day purchase return requires an open-market buy. None is recorded in the last 180 days. Purchases filed earlier are outside the visible history and are not included.

Disclosed ownership

How reported shareholdings evolved

Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.

4 observations · Oct 21, 2026 – Oct 22, 2026. Window ends at the latest available report, not today.

Selected observation · Oct 22, 202654,645 shares reported
Inspect transaction
View exact observations and source transactions
Transaction dateShares held afterFiledSource
Oct 21, 202656,134Oct 23, 2026View transaction
Oct 21, 202654,645Oct 23, 2026View transaction
Oct 22, 202655,145Oct 23, 2026View transaction
Oct 22, 202654,645Oct 23, 2026View transaction

Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.

Gheuens Sarah Insider Activity FAQ

SEC Form 4 context

Who is Gheuens Sarah?

Gheuens Sarah is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001881190.

Which companies has Gheuens Sarah reported transactions for?

AGIOS PHARMACEUTICALS, INC.

When was Gheuens Sarah's latest insider buy?

No open-market insider purchase is recorded in the last 180 days. Earlier filings are outside the visible history.

When was Gheuens Sarah's latest insider sale?

The insider reported a sale at AGIOS PHARMACEUTICALS, INC. on Oct 22, 2026 valued at $18,760.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.